Lung transplant followed by bone marrow transplant for lung and blood failure
Tests lung then bone marrow transplant in adults with lung disease and bone marrow failure.
Key facts
- Who runs it
- Paul Szabolcs
- Where
- Pittsburgh, United StatesSee the 2 sites
- Trial code
- Registry title
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 8 people, planned
- Started
- 19 Apr 2018
- Expected to end
- Dec 2028
- Type of study
- Interventional
- Treatments tested
- CD3/CD19 negative hematopoietic stem cells
- Rituximab
- Alemtuzumab
- Fludarabine
- Thiotepa
- G-CSF
- Hydroxyurea
- Record updated
- 13 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 60 with end stage lung disease and bone marrow failure who meet the criteria for a lung transplant list.
- Age
- 18 to 60 years old, inclusive
- Sex
- All sexes can join.
- Disease stage
- End stage lung disease (for example pulmonary fibrosis or COPD/emphysema) together with bone marrow failure.
- Earlier treatment
- Not stated, except that no live attenuated vaccine may be given within 4 weeks of transplant.
- Biomarker or test result
- Bone marrow failure shown by at least one low blood count in the previous year, confirmed by repeat testing: neutrophils <1500/µL, platelets <100,000/µL, or hemoglobin <12 g/dL.
Main reasons for not taking part
- Underlying cancer (malignant condition)
- HIV positive or HTLV positive
- Pregnant or breastfeeding
- Uncontrolled infection, including uncontrolled lung infection
- Allergy to DMSO or other ingredients of the stem cell product
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Individuals must meet all of the following criteria in order to be eligible for this study
- Subject must be able to understand and provide informed consent
- Male or female, 18 through 60 years old, inclusive, at the time of informed consent
- Meet criteria for UNOS listing for lung transplantation
- Patients must have evidence of end stage lung disease. Examples of such diseases include but are not limited to:; Pulmonary Fibrosis; COPD/Emphysema
- Patients must have evidence of bone marrow failure with abnormal low cell count in at least one hematopoietic line, making the patient a poor candidate for long-term immunosuppressive therapy. Eligible patients must meet at least one of the following criteria:; Unexplained, non-drug induced neutropenia with absolute neutrophils counts of <1500/µL the previous year, confirmed by repeat testing; Unexplained, non-drug induced thrombocytopenia with mean platelets counts of <100,000/µL the previous year, confirmed by repeat testing; Unexplained, non-hemolytic anemia, with a hemoglobin level of < 12 g/dL the previous year, confirmed by repeat testing
- GFR ≥45 mL/min/1.73 m2
- AST, ALT ≤4x upper limit of normal, total bilirubin ≤ 2.5 mg/dL, normal INR, albumin >3.0 g/dL
- Cardiac ejection fraction ≥ 40% or shortening fraction ≥26%
- Negative pregnancy test for females, unless surgically sterilized
- All females of childbearing potential and sexually active males must agree to use a FDA approved method of birth control for up to 24 months after BMT or for as long as they are taking any medication that may harm a pregnancy, an unborn child or may cause birth defect
- Subject will also be counseled regarding the potential risks of infertility following BMT and advised to discuss sperm banking or oocyte harvesting
Who cannot take part
- Recent recipient of any licensed or investigational live attenuated vaccine(s) within 4 weeks of transplant
- Patients who have underlying malignant conditions
- Patients who have non-malignant conditions not requiring BMT
- HIV positive by serology or PCR, HTLV positive by serology. If HTLV serology is positive, it will be confirmed by nucleic acid testing (NAT). If HTLV NAT is negative, subject will remain eligible regardless of HTLV serology result
- Allergy to DMSO or any other ingredient used in the manufacturing of the stem cell product
- Uncontrolled pulmonary infection, as determined by radiographic findings and/or significant clinical deterioration. NOTE: Pulmonary colonization with multiple organisms is common and will not be considered an exclusion criterion
- Uncontrolled infection, as determined by the appropriate imaging and/or confirmatory testing e.g. blood cultures, PCR testing, etc
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
- Individuals who meet any of these criteria are not eligible for this study
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
- Females who are pregnant or who are lactating
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
This trial is currently available in United States.
- Children's Hospital of Pittsburgh of UPMCPittsburgh, United StatesContact: Shawna H McIntyre, RNTaking people
- UPMC PresbyterianPittsburgh, United StatesContact: John McDyer, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.
The group in the trial
- Lung and Bone Marrow TransplantationTreatment being tested
All patients will undergo a cadaveric, partially HLA-matched lung transplantation followed by a CD3+/CD19+ depleted BMT from the same donor. In this study, the investigators will use a ≥1/6 HLA-matched T cell depleted bone marrow transplantation from a cadaveric organ donor with an identical ABO blood type as the recipient. Prior to transplantation, the marrow will be negatively selected for CD3/CD19 using a CliniMACS® depletion device. Subjects will undergo lung transplantation utilizing standard induction regimens selected by the CO-PIs based on the subject's underlying comorbidities and allosensitization. Rituximab may be initiated prior to the lung transplantation with tacrolimus as the ongoing maintenance immunosuppression. Subjects will undergo BMT utilizing CD3+/CD19+-depleted bone marrow with bone marrow conditioning beginning no less than 8 weeks after lung transplantation. Bone marrow will be recovered alongside solid organs and will be processed and cryopreserved.
Treatment: CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, and Hydroxyurea
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure
- Plain-language title
- Lung transplant followed by bone marrow transplant for lung and blood failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT03500731, who can take part
- Record updated
- 13 January 2026